ArticleJournal of functional biomaterials2022
Curcumin-Encapsulated Nanomicelles Improve Cellular Uptake and Cytotoxicity in Cisplatin-Resistant Human Oral Cancer Cells.
Article in Journal of functional biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 46 citations in OpenAlex.
- Targeting oral cancer with curcumin and its structural analogs: molecular mechanisms, pharmacokinetic optimization, and clinical translation.Archives of pharmacal research · 2026Review
- Development of ursolic acid-loaded cubosomal nanocarriers: enhanced dissolution, pharmacokinetics, bioavailability, and anticancer activity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Curcumin and Its Derivatives as Anticancer Agents in Head and Neck Cancer: Molecular Mechanisms and Preclinical Evidence.International journal of molecular sciences · 2026Review
- Extracellular vesicle delivery of Myricetin suppresses ovarian cancer through mitochondrial dynamics by downregulating the ECM1/NF-κB/TGFβ signaling pathway.Scientific reports · 2026Article
- Integrating machine-learning and nanotechnology to quantify pH-modulated oxaliplatin release.Scientific reports · 2025Article
- Bioactive Plant-Derived Compounds as Novel Perspectives in Oral Cancer Alternative Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advances in Nanotechnology-Based Cisplatin Delivery for ORL Cancers: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Ruthenium-enhanced curcumin derivatives target tumor growth and cancer-related inflammation in head and neck cancer models.Frontiers in oncology · 2025Article
- Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma.Cancers · 2024Review
- Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells.Molecules (Basel, Switzerland) · 2023Article
- Article
- TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.Journal of experimental & clinical cancer research : CR · 2023Article
- Therapeutic potential of curcumin and its nanoformulations for treating oral cancer.World journal of methodology · 2023Review
- Biosynthesis of anticancer phytochemical compounds and their chemistry.Frontiers in pharmacology · 2023Review
- Recent advances in tumor targeted polymeric nanoparticles for HNC treatment: Enhancing therapeutic efficacy via engineered and biocompatible drug delivery systems.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
Abstract
Oral cancer has a high mortality rate, which is mostly determined by the stage of the disease at the time of admission. Around half of all patients with oral cancer report with advanced illness. Hitherto, chemotherapy is preferred to treat oral cancer, but the emergence of resistance to anti-cancer drugs is likely to occur after a sequence of treatments. Curcumin is renowned for its anticancer potential but its marred water solubility and poor bioavailability limit its use in treating multidrug-resistant cancers. As part of this investigation, we prepared and characterized Curcumin nanomicelles (CUR-NMs) using DSPE-PEG-2000 and evaluated the anticancer properties of cisplatin-resistant cancer cell lines. The prepared CUR-NMs were sphere-shaped and unilamellar in structure, with a size of 32.60 ± 4.2 nm. CUR-NMs exhibited high entrapment efficiency (82.2%), entrapment content (147.96 µg/mL), and a mean zeta potential of -17.5ζ which is considered moderately stable. The cellular uptake and cytotoxicity studies revealed that CUR-NMs had significantly higher cytotoxicity and cellular uptake in cisplatin drug-resistant oral cancer cell lines and parental oral cancer cells compared to plain curcumin (CUR). The DAPI and FACS analysis corroborated a high percentage of apoptotic cells with CUR-NMs (31.14%) compared to neat CUR (19.72%) treatment. Conclusively, CUR-NMs can potentially be used as an alternative carrier system to improve the therapeutic effects of curcumin in the treatment of cisplatin-resistant human oral cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.